| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/02/2004 | EP1373250A1 Viologen linked acridine based molecule and process for the preparation thereof |
| 01/02/2004 | EP1373249A1 Imidazolidine derivatives, their preparation, and their use as antinflamatory agent |
| 01/02/2004 | EP1373248A1 Benzimidazol derivatives modulate chemokine receptors |
| 01/02/2004 | EP1373244A2 Substituted benzopyranones as telomerase inhibitors |
| 01/02/2004 | EP1373242A1 Dimeric isoflavones |
| 01/02/2004 | EP1373241A1 Method for producing optically active dihydropyrones |
| 01/02/2004 | EP1373240A2 Retinoid x receptor modulators |
| 01/02/2004 | EP1373234A2 Urokinase inhibitors |
| 01/02/2004 | EP1373233A1 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
| 01/02/2004 | EP1373231A1 3-heterocyclylpropanohydroxamic acid pcp inhibitors |
| 01/02/2004 | EP1373218A1 Imidazolyl derivatives useful as histamine h3 receptor ligands |
| 01/02/2004 | EP1373217A1 2-mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors |
| 01/02/2004 | EP1373216A1 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 01/02/2004 | EP1373215A1 Geldanamycin derivative and method of treating cancer using same |
| 01/02/2004 | EP1373205A1 Novel piperidine derivatives as modulators of chemokine receptors |
| 01/02/2004 | EP1373204A2 Heterocyclic compounds |
| 01/02/2004 | EP1373203A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| 01/02/2004 | EP1373192A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad |
| 01/02/2004 | EP1373191A1 Acylated indanyl amines and their use as pharmaceuticals |
| 01/02/2004 | EP1373188A1 Alanine 2,6-dialkoxyphenyl ester derivatives as hypnotics |
| 01/02/2004 | EP1373185A2 Hydrophobic polyamine analogs and methods for their use |
| 01/02/2004 | EP1372785A2 Compositions having improved bioavailability of eletriptan |
| 01/02/2004 | EP1372737A2 Preparation for the prophylaxis of restenosis |
| 01/02/2004 | EP1372735A2 Conjugate of hydroxyalkyl starch and an active agent |
| 01/02/2004 | EP1372734A1 Lectin-directed prodrug delivery system |
| 01/02/2004 | EP1372733A2 Pharmaceutical compositions of active polypeptides for enhanced pharmacological activity through oral and parenteral administration |
| 01/02/2004 | EP1372732A1 Enzyme-activated cytostatic conjugates with integrin ligands |
| 01/02/2004 | EP1372726A1 Methods for reducing fat by administration of adiponectin |
| 01/02/2004 | EP1372720A1 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| 01/02/2004 | EP1372717A2 Combination treatment of pancreatic cancer |
| 01/02/2004 | EP1372716A2 Blood cell production via activation of the hemoglobin scavenger receptor (cd163) |
| 01/02/2004 | EP1372706A2 A novel proteosome-liposaccharide vaccine adjuvant |
| 01/02/2004 | EP1372701A2 Methods of therapy for hiv infection |
| 01/02/2004 | EP1372699A1 Method of improving the growth performance of an animal |
| 01/02/2004 | EP1372696A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/02/2004 | EP1372695A2 Cell damage inhibitor |
| 01/02/2004 | EP1372689A2 Use of ikk-beta inhibitors and method for discovery of said inhibitors |
| 01/02/2004 | EP1372685A1 Use of extracts of the plant litchi chinensis sonn. |
| 01/02/2004 | EP1372679A1 Bioactivity of methyl palmitate obtained from a mangrove plant salvadora persica l |
| 01/02/2004 | EP1372673A2 The use of non-digestible polymeric foams to sequester ingested materials, thereby inhibiting their absorption by the body |
| 01/02/2004 | EP1372671A2 Methylated promoters for intraductal treatment of breast cancer |
| 01/02/2004 | EP1372665A2 Hormone replacement therapy method and its administration form |
| 01/02/2004 | EP1372660A2 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| 01/02/2004 | EP1372657A2 A method of treating proliferative diseases using eg5 inhibitors |
| 01/02/2004 | EP1372656A1 Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors |
| 01/02/2004 | EP1372655A2 Cathepsin cysteine protease inhibitors |
| 01/02/2004 | EP1372654A2 Quinoline inhibitors of hyak1 and hyak3 kinases |
| 01/02/2004 | EP1372653A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 01/02/2004 | EP1372652A2 Combination of a taxane and a cyclin-dependent kinase |
| 01/02/2004 | EP1372651A1 Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity |
| 01/02/2004 | EP1372650A2 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 01/02/2004 | EP1372648A2 Tie2 receptor kinase inhibitors for treating angiogenic diseases |
| 01/02/2004 | EP1372647A2 Use of substituted imidazo 1,2-a]-pyridine compounds as medicaments |
| 01/02/2004 | EP1372644A2 Use of substituted imidazo 1,2-a]-pyridine-3-yl-amide and imidazo 1,2-a]-pyridine-3-yl-amine compounds as medicaments |
| 01/02/2004 | EP1372640A2 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders and a process for the preparation thereof |
| 01/02/2004 | EP1372638A1 Functional role for cannabinoids in autonomic stability during sleep |
| 01/02/2004 | EP1372635A1 Use of creatine for the amelioration of oxidative stress |
| 01/02/2004 | EP1372632A1 Proliferative activator receptor (ppar) compounds |
| 01/02/2004 | EP1372631A1 Method and formula for anti-tumor and anti-matastatic effect |
| 01/02/2004 | EP1372629A2 Therapeutic treatment |
| 01/02/2004 | EP1372626A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 01/02/2004 | EP1372625A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors |
| 01/02/2004 | EP1372616A2 A stable pharmaceutical composition of pravastatin |
| 01/02/2004 | EP1372610A2 Powder inhaler formulations |
| 01/02/2004 | EP1372608A1 Medical aerosol formulations |
| 01/02/2004 | EP1372412A2 Composition improving age-related physiological deficits and increasing longevity |
| 01/02/2004 | EP1250146B1 Use of botulinum toxins for treating diabetes |
| 01/02/2004 | EP1235830B1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS |
| 01/02/2004 | EP1083874B1 Use of a compound for the preparation of a medicament for treating alopecia or promoting hair growth in an animal |
| 01/02/2004 | EP1036062B1 Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors |
| 01/02/2004 | EP0871664B1 Mobilization of hematopoietic stem cells using a chemokine |
| 01/01/2004 | US20040003422 An expression cassette containing the proopiomelanocortin (POMC) enhancer, and a nucleic acid sequence encoding POMC contains at least one exon, wherein a polylinker having an unique site for restriction enzyme is inserted into the exon; gene regulates weight and fat mass |
| 01/01/2004 | US20040003421 Lysosomal proteins produced in the milk of transgenic animals |
| 01/01/2004 | US20040002608 Central nervous system disorders |
| 01/01/2004 | US20040002534 Stem cell factor; signal transduction passageways; anticancer agents |
| 01/01/2004 | US20040002533 Culture product of Streptomyces; lanosterol synthase inhibitor; anticholesterol agents, fungicides |
| 01/01/2004 | US20040002522 Antiinflammatory agents; analgesics |
| 01/01/2004 | US20040002521 Antiinflammatory agents; metalloprotease inhibitor; antiarthritic agents; antiallergens; viricides |
| 01/01/2004 | US20040002519 Mixture of hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, insulin elimination promoter and insulin sensitizer with carrier |
| 01/01/2004 | US20040002518 Anticancer agents; tyrosine kinase inhibitor; wound healing agents |
| 01/01/2004 | US20040002512 Alpha-substituted carboxylic acid derivatives |
| 01/01/2004 | US20040002511 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators |
| 01/01/2004 | US20040002508 Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders |
| 01/01/2004 | US20040002507 Rho-kinase inhibitors |
| 01/01/2004 | US20040002506 Antiproliferative agents; antitumor agents |
| 01/01/2004 | US20040002503 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
| 01/01/2004 | US20040002501 Modulate signal transduction; antitumor, anticancer agents, vision defects, antidiabetic agents, antiinflammatory agents |
| 01/01/2004 | US20040002499 Antitumor agents; anticancer agents; mixture of curcumin and paclitaxel |
| 01/01/2004 | US20040002498 Tricyclic compounds useful as HIV reverse transcriptase inhibitors |
| 01/01/2004 | US20040002494 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| 01/01/2004 | US20040002493 Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient |
| 01/01/2004 | US20040002491 Melatonergic receptors |
| 01/01/2004 | US20040002490 Melatonergic receptors |
| 01/01/2004 | US20040002481 Novel 4-dedimethylaminotetracycline derivatives |
| 01/01/2004 | US20040002480 Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient |
| 01/01/2004 | US20040002468 Methods of treating diabetes and other blood sugar disorders |
| 01/01/2004 | US20040002466 Releasing interferon from complex of interferon and nucleic acids; antitumor agents, viricide, induction immunology response |
| 01/01/2004 | US20040002459 Nucleic acids encoding kringle 1-5 region fragments of plasminogen |
| 01/01/2004 | US20040002454 Administering polypeptides; cardiovascular disorders |
| 01/01/2004 | US20040002423 Remedies |